; 2013 Greenfield's research is focused on brain physiology, particularly on the brain mechanisms of
Parkinson's and
Alzheimer's diseases. She is also known for her role in popularising science. Greenfield has written several books about the brain, regularly gives public lectures, and appears on radio and television. Since 1976, Greenfield has published approximately 200 papers in
peer-reviewed journals, including studies on brain mechanisms involved in addiction and reward, relating to
dopamine systems and other neurochemicals. She investigated the brain mechanisms underlying
attention deficit hyperactivity disorder (
ADHD) as well as the impact of
environmental enrichment. In 1994, she was the first woman to give the
Royal Institution Christmas Lectures, then sponsored by the
BBC. Her lectures were titled "Journey to the centre of the brain". She was appointed Director of the
Royal Institution in 1998. The post was abolished in 2010. The Royal Institution had found itself in a financial crisis following a £22m development programme led by Greenfield and the board. The project ended £3 million in debt. Greenfield subsequently announced that she would be taking her employers to an employment tribunal and her claim would include discrimination. The case was settled out of court. Greenfield's two main positions at Oxford were Tutorial Fellow in Medicine at Lincoln College Oxford, As a result of her recommendations, South Australian Premier Mike Rann made a major funding commitment, backed by the state and federal governments and the private sector, to establish the
Royal Institution of Australia and the Australian Science Media Centre in Adelaide. She has explored the relevance of neuroscience knowledge to education and has used the phrase "mind change", an umbrella term comparable to "climate change", encompassing diverse issues involved in the impact of the 21st-century environment on the brain. In 2013 she co-founded the biotech company Neuro-Bio Ltd which develops diagnostic tests and therapeutics for
Alzheimer's disease. The company has found that the
C terminus of
acetylcholinesterase can be cleaved and that the resulting peptide can kill neurons; the company has also found that a
cyclic peptide analogue could prevent that neuronal death. The company raised around $4 million in 2017. ==Politics==